Condition
Recurrent Breast Inflammatory Carcinoma
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Active Not Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03202316Phase 2Active Not RecruitingPrimary
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
NCT05041101Phase 1Terminated
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Showing all 2 trials